In a recent available Science Daily news explained how new therapy uses synthetic nanofibers to mimic the natural signalling of a protein that is crucial for cartilage formation and maintenance. In a groundbreaking development, researchers have discovered that “dancing molecules” have the potential to heal cartilage damage, offering a promising new treatment for joint injuries and degenerative diseases like osteoarthritis. These molecules, named for their dynamic motion, are designed to move in a way that mimics the natural interactions within the body’s tissues. By actively engaging with cellular structures, these molecules stimulate the regeneration of cartilage by promoting the growth of new cells and the repair of damaged tissue. This innovative approach not only accelerates the healing process but also improves the quality and function of the regenerated cartilage. The success of this technique in preclinical studies suggests that “dancing molecules” could transform the way we treat cartilage injuries, providing a more effective and less invasive alternative to current treatments. As research progresses, this technology holds significant promise for improving the quality of life for millions suffering from joint damage and related conditions.
The article is summarised as “New therapy uses synthetic nanofibers to mimic the natural signaling of a protein that is crucial for cartilage formation and maintenance. Researchers found that intensifying the motion of molecules within the nanofibers led to more components needed for regeneration. After just four hours, the treatment activated the gene expression necessary to generate cartilage. Therapy could be used to treat osteoarthritis, which affects nearly 530 million people worldwide.” The full article can be accessed here.
The recent news published in Drug Discovery News with entitled “Circular RNA: a new era in therapeutics”. The article has reported that “Originally regarded as a genetic anomaly or an experimental artifact, circular RNA (circRNA) garnered attention after scientists discovered it had a functional role in human cells. In 2011, Erik Digman Wiklund, then a molecular biology graduate student at Aarhus University and now Circio’s Chief Executive Officer, published the first study describing a functional human circRNA”. The news quoted Erik that “I forgot about circRNA after that,”. Further, he said, recalling his transition from academia to a business career. A decade later, as circRNA emerged as a promising therapeutic avenue, Wiklund revisited his earlier work, spurred by its newfound popularity. After persuading a former laboratory colleague to join him, they founded a company aimed at developing innovative circRNA medicines for rare diseases, vaccines, and cancer. While circRNA therapeutics are still in early stages, Wiklund’s team has demonstrated circRNA’s superior and enduring protein expression compared to traditional mRNA vectors, hinting at its potential to redefine DNA and virus-based therapies in the future. More about the topic can be accessed here.